Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06806657 · ClinicalTrials.gov registry record · Phase 4
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
A Phase 4 study of Hereditary Angioedema, sponsored by CSL Behring.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 10
- Study locations
NCT06806657 is a Phase 4 study of Hereditary Angioedema that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 30 participants, below the 74-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (59% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT06806657, a Phase 4 study of Hereditary Angioedema, is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.
Conditions Studied
Interventions
- BIOLOGICAL Garadacimab
Study Locations (10)
Other
- Clinique Spécialisée en Allergie de la Capitale - Québec
- HZRM Hämophilie Zentrum Rhein Main GmbH - Frankfurt
- Hautklinik und Poliklinik der Universitätsklinik Mainz - Mainz
California
- Donald Levy M.D. - Orange
- Raffi Tachdjian MD, Inc. - Santa Monica
Arizona
- Research Solutions of Arizona - Litchfield Park
Arkansas
- Allergy and Asthma Clinic of Northwest Arkansas - Bentonville
Ohio
- Bernstein Clinical Research Center, LLC - Cincinnati
Utah
- Chronicle Bio - West Valley City
Quebec
- Montreal Clinical Research Institute - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-19 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06806657
The ClinicalTrials.gov registry entry for NCT06806657 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (59% lower). The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Angioedema appearing as the primary indexed condition, and to 1 intervention - of which Garadacimab is the first listed.
NCT06806657 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06806657 about?
NCT06806657 is a clinical study titled "Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab". This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 month...
What is the current status of trial NCT06806657?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-03-19. Estimated completion is 2026-06-15.
What conditions does trial NCT06806657 study?
This clinical trial studies the following conditions: Hereditary Angioedema.
What interventions are being tested in trial NCT06806657?
The interventions under investigation include: Garadacimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06806657?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06806657 being conducted?
This trial has 10 study locations across Arizona, Arkansas, California, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
RECRUITING · Phase 3
-
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 2
-
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.